avadomide
Small moleculeexperimental
Clinical trial activity
16 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 19, 2011 (NCT01421524)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Glioblastoma · Phase 1
- Healthy Volunteers · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 1
- Renal Insufficiency · Phase 1
Mechanism of action
- Zinc finger protein AiolosDEGRADER
IKZF3 degrader
- DNA-binding protein IkarosDEGRADER
degrader - IKZF1
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc2cccc(N)c2c(=O)n1C1CCC(=O)NC1=O- Mol. weight
- 286.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989934 ↗
Also known as
- 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione
- cc-122
- cc-122
- cc-122
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05979857 | Early Phase 1 (Phase 1) | Mar 15, 2024 | Salarius Pharmaceuticals, LLC |
| NCT05688475 | Phase 1 | Apr 11, 2023 | Bristol-Myers Squibb |
| NCT03834623 | Phase 2 | May 14, 2019 | Bristol-Myers Squibb, Celgene, University of South Florida |
| NCT03310619 | Phase 1/Phase 2 (Phase 2) | Nov 28, 2017 | Celgene, Juno Therapeutics, Inc. |
| NCT03340662 | Phase 1 | Nov 9, 2017 | Celgene |
| NCT03283202 | Phase 1/Phase 2 (Phase 2) | Oct 4, 2017 | Celgene |
| NCT03097016 | Phase 1 | Mar 30, 2017 | Celgene |
| NCT02859324 | Phase 1/Phase 2 (Phase 2) | Sep 20, 2016 | Celgene |
| NCT02509039 | Phase 1 | Aug 1, 2015 | Celgene |
| NCT02406742 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2015 | Celgene |
| NCT02417285 | Phase 1 | May 22, 2015 | Celgene |
| NCT02323906 | Phase 1 | Jan 16, 2015 | Celgene |
| NCT02234999 | Phase 1 | Sep 1, 2014 | Celgene |
| NCT02049528 | Phase 1 | Jan 1, 2014 | Celgene |
| NCT02031419 | Phase 1 | Dec 18, 2013 | Celgene |
| NCT01421524 | Phase 1 | Sep 19, 2011 | Celgene |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 14 | 13 | 2 | 2011 |
| Bristol-Myers Squibb | For profit | 2 | 1 | 2 | 2019 |
| Juno Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2017 |
| Salarius Pharmaceuticals, LLC | For profit | 1 | 1 | 1 | 2024 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1